Wegener Antje, VP of Translational Medicine
Professional Overview
Wegener Antje is an accomplished pharmaceutical executive with extensive expertise in drug development and clinical program management. As the Vice President of Translational Medicine at Mariana Oncology, she is responsible for leading the company's efforts to bridge the gap between preclinical research and clinical implementation, driving the development of innovative cancer therapies.
Experience Summary
Current Role
As the VP of Translational Medicine at Mariana Oncology, Wegener Antje is responsible for overseeing the translation of scientific discoveries into clinical-stage programs. She leads a team of researchers and clinicians in designing and executing translational studies that optimize the clinical potential of novel oncology compounds. Under her guidance, Mariana Oncology has accelerated the development of several promising drug candidates, positioning the company as a leader in the field of translational medicine.
Career Progression
Wegener Antje's career in the pharmaceutical industry spans over two decades, during which she has held various leadership positions with a focus on clinical development and drug safety. Prior to joining Mariana Oncology, she served as the VP of Clinical Development at Radiopharm Theranostics, where she successfully led the global clinical program for a novel radiopharmaceutical therapy. Before that, she held the role of Global Clinical Program Leader at Advanced Accelerator Applications, where she coordinated the international development of a groundbreaking cancer treatment. Wegener Antje's extensive experience in both small and large pharmaceutical companies has equipped her with a deep understanding of the complexities involved in translating scientific discoveries into effective patient therapies.
Academic Background
Wegener Antje holds a Ph.D. in Pharmacology from the University of Paris, where her research focused on the development of novel cancer treatment strategies. She is a recognized expert in the field of oncology, with numerous publications in peer-reviewed journals and presentations at industry conferences.
Areas of Expertise
- Oncology drug development
- Translational medicine and biomarker-driven research
- Clinical program design and execution
- Global regulatory strategy and compliance
- Cross-functional team leadership and collaboration
Professional Impact
Wegener Antje's contributions to the pharmaceutical industry have been significant. At Mariana Oncology, she has spearheaded the development of several innovative cancer therapies, accelerating the translation of cutting-edge science into clinical-stage programs. Her expertise in translational medicine has been instrumental in enhancing the company's pipeline and positioning it as a leader in the field of oncology drug development.
Conclusion
With her extensive experience, deep technical expertise, and proven track record of success, Wegener Antje is a valuable asset to Mariana Oncology and the broader pharmaceutical industry. As the VP of Translational Medicine, she continues to drive the development of transformative cancer treatments, making a meaningful impact on the lives of patients worldwide.
